Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bruce Heller

Dermatology New York, NY Medical Doctor

NPI 1912973991 CMS profile 40942

315 West 57Th St, Ste Ll3, New York, NY 10019

Open in the dashboard

General payments

$1,102

83 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bruce Heller of New York, NY is reported in the CMS Open Payments database as having received $1,102 across 83 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 36th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $26 1
2020 General $127 8
2019 General $950 74

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bruce Heller
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Bruce Heller were reported at $26. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Bruce Heller Dermatology median Middle half National median
2019 $950 $454 $129–$1,240 $163
2020 $127 $235 $81–$756 $114
2021 $0 $377 $108–$1,108 $132
2022 $0 $514 $143–$1,391 $149
2023 $0 $607 $159–$1,674 $160
2024 $0 $751 $204–$1,903 $164
2025 $26 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Encore Dermatology Inc. $199 15 payments
  2. LEO Pharma Inc. $190 19 payments
  3. Galderma Laboratories, L.P. $185 21 payments
  4. Merz North America, Inc. $107 1 payment
  5. Sandoz Inc. $51 3 payments
  6. Celgene Corporation $48 3 payments
  7. Glenmark Therapeutics Inc. $34 2 payments
  8. Novum Pharma, LLC $30 2 payments
  9. Ortho Dermatologics, a division of Bausch Health US, LLC $30 2 payments
  10. EPI Health, LLC $28 3 payments
  11. Other $201 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,102 83 payments
Products named General payments · program years 2019–2025
  1. Impoyz $199 15 payments
  2. ENSTILAR $190 19 payments
  3. EPIDUO FORTE $107 11 payments
  4. Xeomin $107 1 payment
  5. ASCLERA $107 1 payment
  6. SOOLANTRA $105 14 payments
  7. KERYDIN $51 3 payments
  8. ORACEA $50 5 payments
  9. Mupirocin Cream $34 2 payments
  10. Alcortin A $30 2 payments
  11. Other $402 31 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,378

Median for Dermatology: 534

Drug cost

$27,162

Median for Dermatology: $67,151

Branded share of claims

7.8%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fluorouracil Generic 103 $7,490
Fluocinolone Acetonide Generic 59 $3,060
Mupirocin Generic 352 $2,088
Hydrocortisone Generic 236 $1,706
Clindamycin Phosphate Generic 15 $1,692
Triamcinolone Acetonide Generic 180 $1,436
Desonide Generic 35 $1,337
Ciclopirox Generic 47 $1,217
Ciclopirox Ciclopirox Olamine Brand 52 $1,002
Fluocinonide Generic 25 $981

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$258,616

Of which drugs: $146

Medicare patients

738

Average age 75

Services billed

7,124

381 women, 357 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 48%
Ischemic heart disease 36%
Diabetes 31%
Chronic kidney disease 19%
Depression 18%
Atrial fibrillation 16%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 115 199 $146

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

83 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record